Platelet activation in patients with chronic pulmonary heart disease. Effect of dipyridamole treatment

Chin Med J (Engl). 1995 Feb;108(2):95-7.


Plasma levels of beta-thromboglobulin (beta-TG), platelet factor 4(PF4) and platelet aggregation rate (PAR) were measured in remission phase of 15 patients affected with chronic pulmonary heart disease (CPHD). beta-TG, beta-TG/PF4, PF4 and PAR were significantly higher in the patients than in controls (P < 0.01 and 0.05, respectively). After 10 days of treatment with Dipyridamole 100mg tid, beta-TG, beta-TG/PF4 and PF4 decreased significantly compared with pretreatment values (P < 0.01 and 0.05, respectively). The results suggest that in vivo platelet activation is indeed present in patients with CPHD and that dipyridamole can antagonize platelet activation in vivo.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Dipyridamole / pharmacology
  • Dipyridamole / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / pharmacology
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Factor 4 / metabolism
  • Pulmonary Heart Disease / blood*
  • Pulmonary Heart Disease / drug therapy
  • beta-Thromboglobulin / metabolism


  • Platelet Aggregation Inhibitors
  • beta-Thromboglobulin
  • Platelet Factor 4
  • Dipyridamole